Guillain-Barré syndrome and its treatment.
Guillain-Barré syndrome typically presents with an acute ascending areflexic weakness, progressing over 4 weeks or less. The most common form of the disease is an acute inflammatory demyelinating polyneuropathy, but other forms with primarily axonal pathologies are well documented. The association of Guillain-Barré syndrome with a range of antecedent infections, particularly Campylobacter jejuni enteritis, is also established. A range of serological and neurophysiological investigations can assist in making an accurate diagnosis. Background information about the syndrome and the evidence base for such treatments are discussed herein.
Douglas
Michael R
MR
Department of Neurology, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK. m.r.douglas@blueyonder.co.uk
Winer
John B
JB
D020275:Guillain-Barre Syndrome / Q000097:blood / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D006801:Humans